Press Releases

Not for Dissemination in the US or through US Newswire Services

TORONTO, May 21, 2024 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), is providing an update on its dispute with Sergio Martines and NATURALE SCIENCE INC. (together the plaintiffs), the former Chief Executive Officer of Canapar Corp. (“Canapar”) and a former director of the Company as reported in its audited financial... (continue reading...)

• Trial's first and second cohorts maintaining signs of potential efficacy out to 24 weeks
• Data from  the second cohort showed improvements in eosinophil counts and histological scores out to 12 weeks suggesting a dose response over the first cohort
• Data from the trial's third cohort suggest improvements in patient-reported symptoms and histological outcomes at 12 weeks
• EP-104GI showed an encouraging safety profile in all three cohorts

VICTORIA, BC, May 21, 2024... (continue reading...)

WINNIPEG, Manitoba, May 21, 2024 (GLOBE NEWSWIRE) -- (TSX: NFI, OTC: NFYEF, TSX: NFI.DB) NFI Group Inc. (NFI), a leading independent bus and coach manufacturer and a leader in zero-emission electric mass mobility solutions, is pleased to announce the selection of John Proven as the new President of NFI Parts and ARBOC Specialty Vehicles (ARBOC). John will start his new role on June 3, 2024, reporting directly to NFI’s President and Chief Executive Officer, Paul... (continue reading...)

CALGARY, Alberta, May 21, 2024 (GLOBE NEWSWIRE) -- Helium Evolution Incorporated (TSXV: HEVI) ("HEVI" or the "Company"), a Canadian-based helium exploration company focused on developing assets in southern Saskatchewan, today announced the filing of the Company’s interim condensed financial statements and associated management’s discussion and analysis for the three months ended March 31, 2024 (the “Q1 Report”).

Complete details of the Q1 Report are... (continue reading...)

SUNNYVALE, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that, following approval by the Company's stockholders and its Board of Directors, the Company intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 15 pre-split shares. The reverse stock split will become... (continue reading...)